background: in helical tomotherapy (ht), the scaling factor (sf) is the time in seconds that each leaf viewing a target would need to be open to deliver the prescribed dose. the sf is patient-specific and is used to calculate the rotational period of the gantry, and the total treatment time (ttt) of the ht. the sf is generally difficult to estimate. currently, it takes about one hour to fully o...

background: metastatic prostate cancer is one of the most important cancers among men worldwide. androgen ablation therapy can be used in treatment of these patients; however, most will progress to metastatic hormone-refractory prostate cancer. in this regard, docetaxel has been approved to treat metastatic hormone-refractory prostate cancer in the united states. in this study, we aimed to inve...

abstract prostate cancer is one of the life threatening disorders of male. although, over the last two decades, a high rate of overdiagnosis, and overtreatment has lowered the incidence rate of prostate cancer, the treatment or prevention strategies are not enough to control the high rate of disease related mortality. current medical treatment approaches include surgery, radiation therapy, chem...

Prostate cancer is the most common and second leading cause of death among men in the world. Nowadays, radiotherapy has been known as one of the most affecting methods for prostate cancer treatment. Nevertheless, radiotherapy is accompanied by the concern of developing secondary cancers by the scattered radiation to the neighbor  organs at risk. Several studies have shown that secondary cancers...

in the recent years, interstitial brachytherapy implantation has become the treatment of choice for early stage prostate cancer patients. treatment of prostate cancer with radiation is traced back to 1909. originally this treatment modality was very crude and could not gain much popularity till 1982. advancements in radioactive source designs, introduction of new low energy radioactive sources,...

Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein, which is anchored in the cell membrane of prostate epithelial cells. It is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Although, 177Lu-PSMA has been recently introduced for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC) with co...

In the recent years, interstitial brachytherapy implantation has become the treatment of choice for early stage prostate cancer patients. Treatment of prostate cancer with radiation is traced back to 1909. Originally this treatment modality was very crude and could not gain much popularity till 1982. Advancements in radioactive source designs, introduction of new low energy radioactive sources,...

Introduction: The accuracy of the patient setup and tumor location are major factors that determine the efficacy of radiotherapy treatment planning. In the prostate radiotherapy, reproducibility of the prostate location for each treatment fraction is problematic owing to varying filling of the rectum and bladder. According to this, the aim of this study was to measure the inte...